Bayer AG’s dermatology unit is attracting interest from a number of health-care and private equity firms as the German company seeks to raise cash for its $66 billion acquisition of Monsanto Co., according to people with knowledge of the matter.
Teva Pharmaceutical Industries Ltd., Perrigo Co. and Sun Pharmaceutical Industries Ltd. are among companies considering offers, said the people, who asked not to be named because the deliberations are private. Buyout firms including KKR & Co., Nordic Capital, Bain Capital, Blackstone Group LP and Cinven Ltd. may also look at the asset, the people said.
Initial offers are due in the coming weeks, the people said. The discussions are at an early stage and no final decisions have been made, they said. Bayer is working with JPMorgan Chase & Co. on the sale, which could fetch more than 1 billion euros ($1.1 billion), people familiar with the process said earlier this month.
